Effect of Ephedrine vs. Norepinephrine on Prevention of Fetal Acidosis During Cesarean Section Under Spinal Anesthesia

Launched by MEHMET ÖZKILIÇ · Apr 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how two medications, ephedrine and norepinephrine, affect babies during cesarean deliveries when the mother receives spinal anesthesia. Low blood pressure, a common side effect of spinal anesthesia, can impact blood flow to the baby and potentially lead to a condition called acidosis. The researchers want to find out which medication is better at keeping both the mother’s blood pressure stable and the baby safe, by checking the baby's blood acidity levels after birth, as well as looking at the mother's vital signs and the baby's health scores.

To be eligible for this trial, pregnant women aged 18 to 45 who are having a single baby and are at least 37 weeks along can participate. They need to be scheduled for an elective cesarean section and be in good health (classified as ASA I or II). However, women with certain health issues, such as allergies to these medications, multiple pregnancies, or specific pregnancy complications, will not be able to join. Participants can expect to receive one of the two medications during their surgery and will be closely monitored for their health and the health of their baby throughout the process. If you're considering participation, it's important to discuss it with your healthcare provider to ensure it’s the right choice for you.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant women aged between 18 and 45 years
• • Singleton pregnancy at ≥ 37 weeks of gestation
• • Scheduled for elective cesarean section under spinal anesthesia
• • ASA (American Society of Anesthesiologists) physical status classification I or II
• • Ability to understand and sign the informed consent form
• Exclusion Criteria:
• • History of allergy or hypersensitivity to ephedrine or norepinephrine
• • Multiple gestation pregnancies
• • Diagnosis of pre-eclampsia, eclampsia, or other hypertensive disorders of pregnancy
• • Known cardiovascular disease or arrhythmia
• • Placental abnormalities (e.g., placenta previa, placental abruption)
• • Fetal structural or chromosomal anomalies
• • Morbid obesity (BMI \> 40 kg/m²)
• • Refusal to participate or inability to provide informed consent